Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.

Fiskus W, Mill CP, Piel J, Collins M, Hentemann M, Cuglievan B, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Flores LB, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Wang J, Loghavi S, Su X, DiNardo CD, Delwel R, Bhalla KN

Open source

DOI: 10.1002/hem3.70289
Published: 2026 Jan
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/hem3.70289,
  title = {Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.},
  author = {Fiskus W and Mill CP and Piel J and Collins M and Hentemann M and Cuglievan B and Birdwell CE and Das K and Davis JA and Hou H and Jain A and Malovannaya A and Flores LB and Kadia TM and Daver N and Sasaki K and Takahashi K and Hammond D and Wang J and Loghavi S and Su X and DiNardo CD and Delwel R and Bhalla KN},
  year = {2026},
  journal = {HemaSphere},
  doi = {10.1002/hem3.70289},
  url = {https://doi.org/10.1002/hem3.70289}
}

RIS

TY  - JOUR
TI  - Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.
AU  - Fiskus W
AU  - Mill CP
AU  - Piel J
AU  - Collins M
AU  - Hentemann M
AU  - Cuglievan B
AU  - Birdwell CE
AU  - Das K
AU  - Davis JA
AU  - Hou H
AU  - Jain A
AU  - Malovannaya A
AU  - Flores LB
AU  - Kadia TM
AU  - Daver N
AU  - Sasaki K
AU  - Takahashi K
AU  - Hammond D
AU  - Wang J
AU  - Loghavi S
AU  - Su X
AU  - DiNardo CD
AU  - Delwel R
AU  - Bhalla KN
PY  - 2026
JO  - HemaSphere
DO  - 10.1002/hem3.70289
UR  - https://doi.org/10.1002/hem3.70289
ER  -

APA

W, F., CP, M., J, P., M, C., M, H., B, C., CE, B., K, D., JA, D., H, H., A, J., A, M., LB, F., TM, K., N, D., K, S., K, T., D, H., J, W., S, L., X, S., CD, D., R, D., & KN, B. (2026). Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.. HemaSphere. https://doi.org/10.1002/hem3.70289

Source records

pubmed · retrieved 2026-09-25T02:31:49.122Z